SCGB2A1 and B-cell chronic lymphocytic leukemia: The recent studies showed that SCGB2A1, KLF4, and PPP1R14B can differentiate a group of circa 5% of cases with less survival in chronic lymphocytic leukemia (CLL) patients, which might be useful for further research about disease prognostication and drug response in CLL (Orgueira et al., 2019).